Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Y. Emi · SciRah

Researcher profile · Semantic Scholar

Y. Emi

Share profile

Y. Emi — researcher profile on SciRah

h-index: 32
Works: 188
Citations: 3,072

Most-cited papers

Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302)
E. Oki, S. Tokunaga, Y. Emi, T. Kusumoto +16 more
2016Gastric Cancer122 citations Open access
Semantic Scholar
Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
K. Shitara, K. Chin, T. Yoshikawa, H. Katai +8 more
2015Gastric Cancer98 citations Open access
Semantic Scholar
Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives
Y. Maehara, S. Tsujitani, H. Saeki, E. Oki +7 more
2011Surgery today (Print)91 citations Open access
Semantic Scholar
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study
E. Oki, Y. Emi, H. Kojima, Jun Higashijima +15 more
2015International Journal of Clinical Oncology89 citations
Semantic Scholar
Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
N. Fuse, H. Bando, K. Chin, S. Ito +13 more
2016Gastric Cancer82 citations Open access
Semantic Scholar
In-Hospital Mortality After a Surgical Resection for Esophageal Cancer: Analyses of the Associated Factors and Historical Changes
M. Morita, Tomonori Nakanoko, Yoshihiko Fujinaka, Nobuhide Kubo +7 more
2011Annals of Surgical Oncology64 citations
Semantic Scholar
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
S. Hironaka, N. Sugimoto, K. Yamaguchi, T. Moriwaki +15 more
2016The Lancet Oncology61 citations
Semantic Scholar
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
E. Oki, Y. Emi, T. Yamanaka, H. Uetake +15 more
2019British Journal of Cancer55 citations Open access
Semantic Scholar
Recent advances in treatment for colorectal liver metastasis
E. Oki, K. Ando, R. Nakanishi, M. Sugiyama +7 more
2018Annals of Gastroenterological Surgery52 citations Open access
Semantic Scholar
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First‐line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
E. Oki, Takeshi Kato, H. Bando, T. Yoshino +15 more
2018Clinical colorectal cancer48 citations Open access
Semantic Scholar
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
E. Oki, A. Murata, Kazuhiro Yoshida, K. Maeda +13 more
2016Annals of Oncology47 citations Open access
Semantic Scholar
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
K. Imai, Y. Emi, K. Iyama, T. Beppu +7 more
2014European Journal of Surgical Oncology47 citations
Semantic Scholar
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
Yoshiaki Nakamura, T. Yamanaka, K. Chin, Haruhiko Cho +14 more
2018Annals of Surgical Oncology46 citations
Semantic Scholar
Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer
E. Oki, Y. Emi, T. Kusumoto, Y. Sakaguchi +16 more
2014Annals of Surgical Oncology36 citations
Semantic Scholar
Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial
Y. Maehara, K. Shirabe, S. Kohnoe, Y. Emi +25 more
2017Surgery today (Print)35 citations
Semantic Scholar
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B
S. Yuki, K. Shinozaki, T. Kashiwada, T. Kusumoto +14 more
2019Cancer Chemotherapy and Pharmacology27 citations
Semantic Scholar
Possibility of Müller Cell Dysfunction as the Pathogenesis of Paclitaxel Maculopathy.
S. Nakao, Y. Ikeda, Y. Emi, T. Ishibashi
2016Ophthalmic Surgery Lasers and Imaging Retina26 citations
Semantic Scholar
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
T. Beppu, Y. Emi, S. Tokunaga, E. Oki +13 more
2014Anticancer Research23 citations
Semantic Scholar
Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases
M. Ninomiya, Y. Emi, T. Motomura, T. Tomino +7 more
2021International Journal of Clinical Oncology21 citations
Semantic Scholar
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
M. Takatsuki, S. Tokunaga, S. Uchida, Masahiko Sakoda +11 more
2016European Journal of Surgical Oncology20 citations Open access
Semantic Scholar
Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes
H. Nitta, T. Shimose, Y. Emi, T. Imamura +12 more
2016Medical Oncology19 citations
Semantic Scholar
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)
E. Oki, Y. Emi, Y. Miyamoto, A. Kabashima +17 more
2015Annals of Surgical Oncology16 citations
Semantic Scholar
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial—EPOC 2 (JFMC49-1601-C5)
Y. Tanaka, H. Takeuchi, Y. Nakashima, H. Nagano +15 more
2021ESMO Open15 citations Open access
Semantic Scholar
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Y. Miyamoto, E. Oki, Y. Emi, S. Tokunaga +8 more
2018Anticancer Research15 citations Open access
Semantic Scholar
A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
T. Okamoto, T. Yano, M. Shimokawa, S. Takeo +18 more
2018Lung Cancer15 citations
Semantic Scholar
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma
H. Saeki, Tomoko Jogo, Tetsuro Kawazoe, Tomohiro Kamori +19 more
2020Annals of Surgery13 citations
Semantic Scholar
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
Y. Ogata, M. Shimokawa, Takaho Tanaka, Y. Emi +10 more
2015International Journal of Clinical Oncology13 citations Open access
Semantic Scholar
Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites
M. Sugiyama, Y. Kakeji, S. Tsujitani, Y. Harada +9 more
2011Molecular Cancer Therapeutics12 citations Open access
Semantic Scholar
Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)
H. Tanioka, Y. Miyamoto, A. Tsuji, M. Asayama +14 more
2018Oncology10 citations
Semantic Scholar
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)
Y. Miyamoto, A. Tsuji, H. Tanioka, S. Maekawa +12 more
2016International Journal of Clinical Oncology10 citations
Semantic Scholar
Simultaneous total gastrectomy and endovascular repair of an abdominal aortic aneurysm: Report of a case
Keiji Yoshinaga, Rintaro Yoshida, A. Guntani, Takuya Matsumoto +6 more
2011Surgery today (Print)10 citations
Semantic Scholar
O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
H. Shirasu, H. Taniguchi, J. Watanabe, M. Kotaka +18 more
2021Annals of Oncology9 citations Open access
Semantic Scholar
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)
K. Ando, Y. Emi, T. Suenaga, M. Hamanoue +13 more
2017International Journal of Clinical Oncology8 citations
Semantic Scholar
Phase II study of long‐course chemoradiotherapy followed by consolidation chemotherapy as total neoadjuvant therapy in locally advanced rectal cancer in Japan: ENSEMBLE‐2
Y. Kagawa, K. Ando, Mamoru Uemura, J. Watanabe +8 more
2024Annals of Gastroenterological Surgery7 citations Open access
Semantic Scholar
Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)
E. Oki, Y. Emi, Y. Akagi, S. Tokunaga +10 more
2013Oncology7 citations
Semantic Scholar
Analysis of oxaliplatin-induced sensory neurotoxicity (sNT) in patients receiving FIREFOX, alternating regimen of mFOLFOX-6 and FOLFIRI, with metastatic colorectal cancer (MCRC): Results from combined analysis of KSCC0501 and KSCC0701.
Tetsuya Kusumoto, Y. Emi, Y. Kakeji, Y. Akagi +5 more
2011Journal of Clinical Oncology7 citations
Semantic Scholar
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)
Takao Takahashi, Y. Emi, E. Oki, Kazuma Kobayashi +10 more
2016Cancer Chemotherapy and Pharmacology6 citations
Semantic Scholar
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
A. Murata, Kazuhiro Yoshida, K. Maeda, K. Ikejiri +12 more
20156 citations Open access
Semantic Scholar
Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan
H. Saeki, Y. Emi, R. Kumashiro, Hajime Otsu +9 more
2013Surgery today (Print)6 citations
Semantic Scholar
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients
Y. Emi, Y. Kakeji, E. Oki, H. Saeki +13 more
2013International Journal of Clinical Oncology6 citations
Semantic Scholar
Liver Parenchyma Perforation following Endoscopic Retrograde Cholangiopancreatography
Hiroto Kayashima, T. Ikegami, Y. Kasagi, Gen Hidaka +6 more
2011Case Reports in Gastroenterology6 citations Open access
Semantic Scholar
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: A Japanese experience
H. Baba, N. Hayashi, Y. Emi, Y. Kakeji +18 more
2011Surgery today (Print)6 citations
Semantic Scholar
Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
Takao Takahashi, K. Ishida, Y. Emi, M. Sakamoto +12 more
2022Cancers5 citations Open access
Semantic Scholar
Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.
H. Yukami, Yoshiaki Nakamura, J. Watanabe, M. Kotaka +16 more
20215 citations
Semantic Scholar
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival
K. Ando, Y. Emi, N. Miyanari, A. Tsuji +13 more
2020International Journal of Clinical Oncology5 citations
Semantic Scholar
Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: Initial results from KSCC1105, a trastuzumab observational cohort study.
A. Makiyama, M. Shimokawa, T. Kashiwada, I. Takahashi +10 more
20175 citations
Semantic Scholar
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
K. Miwa, E. Oki, Y. Emi, H. Saeki +13 more
2016International Journal of Clinical Oncology5 citations
Semantic Scholar
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104)
H. Satake, M. Iwatsuki, Yoshikazu Uenosono, T. Shiraishi +13 more
2016Cancer Chemotherapy and Pharmacology5 citations Open access
Semantic Scholar
A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).
Y. Miyamoto, S. Yuki, M. Shimokawa, H. Tanioka +13 more
20164 citations
Semantic Scholar
[Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers].
Y. Maehara, E. Oki, H. Saeki, E. Tokunaga +8 more
2016Gan to kagaku ryoho. Cancer & chemotherapy4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Oki×37
Invite
E. Oki — researcher profile on SciRah
Y. Maehara×34
Invite
Y. Maehara — researcher profile on SciRah
H. Saeki×25
Invite
H. Saeki — researcher profile on SciRah
H. Baba×24
Invite
H. Baba — researcher profile on SciRah

×19

Invite

Y. Kakeji — researcher profile on SciRah

Invite

Y. Akagi — researcher profile on SciRah

M. Shimokawa×15

Invite

M. Shimokawa — researcher profile on SciRah

S. Natsugoe×11

Invite

S. Natsugoe — researcher profile on SciRah

Invite

Y. Ogata — researcher profile on SciRah

S. Tokunaga×10

Invite

S. Tokunaga — researcher profile on SciRah

Invite

A. Tsuji — researcher profile on SciRah

Kazuhiro Yoshida×9

Invite

Kazuhiro Yoshida — researcher profile on SciRah